The AI-driven wearable sensor demonstrates high accuracy in reducing nighttime scratching for atopic dermatitis, improving patient outcomes and sleep quality.

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology. “We understand that ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Incyte Corp on Monday forecast annual sales of its skin disorder treatment Opzelura below Wall Street estimates, sending the drugmaker's shares down as much as 9% in afternoon trade. Opzelura is used ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...

For children with atopic dermatitis, early childhood stressful life events are associated with an increased risk for disease activity.